Label: ERYTHROMYCIN solution

  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated June 13, 2022

If you are a consumer or patient please visit this version.


    For Topical Use Only

    Not for Ophthalmic Use

    Rx Only


    Erythromycin topical solution, USP 2% contains erythromycin, USP for topical dermatologic use. Erythromycin is a macrolide antibiotic produced from a strain of Saccaropolyspora erythraea (formerly Streptomyces erythreus). It is a base and readily forms salts with acids. Chemically, erythromycin is: (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-0-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy -3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-ß-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione. It has the following structural formula:

    Structural Formula

    Molecular Formula: C37H67NO13

    Molecular Weight: 733.94

    Erythromycin, USP is a white or slightly yellow, crystalline powder that is  soluble in water, alcohol, chloroform and in ether.

    Each mL of erythromycin topical solution, USP 2% contains 20 mg of erythromycin base in a vehicle consisting of alcohol (66%), citric acid, and propylene glycol.


    The exact mechanism by which erythromycin reduces lesions of acne vulgaris is not fully known; however, the effect appears to be due in part to the antibacterial activity of the drug.


    Erythromycin acts by inhibition of protein synthesis in susceptible organisms by reversibly binding to 50S ribosomal subunits, thereby inhibiting translocation of aminoacyl transfer-RNA and inhibiting polypeptide synthesis. Antagonism has been demonstrated in vitro between erythromycin, lincomycin, chloramphenicol, and clindamycin.


    Erythromycin topical solution, 2% is indicated for the topical treatment of acne vulgaris.


    Erythromycin topical solution, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.


    Pseudomembranous colitis has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

    Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one primary cause of “antibiotic-associated colitis”.

    After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against C. difficile colitis.



    For topical use only; not for ophthalmic use. Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating or abrasive agents.

    The use of antibiotic agents may be associated with the overgrowth of antibiotic-resistant organisms. If this occurs, discontinue use and take appropriate measures.

    Avoid contact with eyes and all mucous membranes.

    Information for Patients 

    Patients using erythromycin topical solution, 2% should receive the following information and instructions:

    1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes, nose, mouth, and all mucous membranes.
    2. This medication should not be used for any disorder other than that for which it was prescribed.
    3. Patients should not use any other topical acne medication unless otherwise directed by their physician.
    4. Patients should report to their physician any signs of local adverse reactions.

    Carcinogenesis, Mutagenesis, Impairment of Fertility 

    No animal studies have been performed to evaluate the carcinogenic and mutagenic potential or effects on fertility of topical erythromycin. However, long-term (2 years) oral studies in rats with erythromycin ethylsuccinate and erythromycin base did not provide evidence of tumorigenicity. There was no apparent effect on male or female fertility in rats fed erythromycin (base) at levels up to 0.25% of diet.


    There was no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25% of diet) prior to and during mating, during gestation and through weaning of two successive litters.

    There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed. Erythromycin has been reported to cross the placental barrier in humans, but fetal plasma levels are generally low.

    Nursing Mothers 

    It is not known whether erythromycin is excreted in human milk after topical application. However, erythromycin is excreted in human milk following oral and parenteral erythromycin administration. Therefore, caution should be exercised when erythromycin is administered to a nursing woman.

    Pediatric Use 

    Safety and effectiveness of this product in pediatric patients have not been established.


    The following local adverse reactions have been reported occasionally: peeling, dryness, itching, erythema, and oiliness. Irritation of the eyes and tenderness of the skin have also been reported with topical use of erythromycin. Generalized urticarial reactions possibly related to the use of erythromycin, which required systemic steroid therapy have been reported.

    To report SUSPECTED ADVERSE REACTIONS, contact Saptalis Pharmaceuticals, LLC at 1-833-727-8254 or FDA at 1-­800‑FDA‑1088 or


    Erythromycin topical solution, 2% should be applied over the affected areas twice a day (morning and evening) after the skin is thoroughly washed with warm water and soap and patted dry. Acne lesions on the face, neck, shoulders, chest, and back may be treated in this manner.

    This medication should be applied with applicator top. If fingertips are used, wash hands after application. Drying and peeling may be controlled by reducing the frequency of applications.


    Erythromycin topical solution, USP 2% is available as follows:

    60 mL bottle with applicator (NDC 42571-384-25)

    Store at 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Keep container tightly closed.


    Manufactured by:
    Saptalis Pharmaceuticals, LLC
    Hauppauge, NY 11788

    Distributed by:
    Micro Labs USA, Inc.
    Somerset, NJ 08873

    Rev. 01/22-R2

  • Principal dispaly panel-Label

    NDC 42571-384-25

    Erythromycin Topical Solution, USP 2%

    For Topical Use Only

    Not for Ophthalmic Use

    Rx only

    60 mL


  • Principal dispaly panel-Carton

    NDC 42571-384-25

    Erythromycin Topical Solution, USP 2%

    For Topical Use Only

    Not for Ophthalmic Use

    Rx only

    60 mL


    erythromycin solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:42571-384
    Route of AdministrationTOPICAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Inactive Ingredients
    Ingredient NameStrength
    ALCOHOL (UNII: 3K9958V90M)  
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:42571-384-251 in 1 CARTON06/04/2021
    160 mL in 1 BOTTLE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Labeler - MICRO LABS LIMITED (862174955)
    Registrant - Saptalis Pharmaceuticals, LLC. (080145868)
    NameAddressID/FEIBusiness Operations
    Saptalis Pharmaceuticals, LLC.080145868manufacture(42571-384)